grain-elipse1
grain-elipse

CRISPR-Based HIV Gene Therapy Administered To First Human Patient

Published September 29, 2022
Categories: Health Science
Eternity Life Clinics - CRISPR-Based HIV Gene Therapy Administered To First Human Patient

Scientists at the Lewis Katz School of Medicine at Temple University and representatives of Excision BioTherapeutics together succeeded in applying an HIV gene therapy to humans for the first time. The researchers themselves say that this is a real breakthrough in medicine and the currently known ways to fight HIV.

When using the CRISPR genomic editor, the specialists injected the patient with a special solution, which should edit the biological changes that occurred as a result of the virus entering the body. The first attempt was safe, so the doctors plan to continue the trials with 18 more patients. This treatment could usher in “a new era in medicine” by making “HIV therapy much easier and more effective”.

Prior to this, doctors tried to destroy traces of the presence of HIV in the DNA of 23 mice using the CRISPR/Cas9 genomic editor, which showed some effectiveness.

Why might a new drug be more effective?

The therapeutic drug EBT-101, which will of course be subject to further research and development, uses CRISPR/Cas genome correction mechanism. It is developed on basis of natural mechanism by which bacteria protect themselves from viruses, and allows you to “cut out” the viral DNA that has integrated into the genome. In preclinical trials, EBT-101 was able to remove HIV genetic information in several cell lines – primary human cells, as well as animal cells, including primates.

CRISPR/Cas9 and two guide RNAs will get cells using the non-pathogenic AAV9 virus, which is already being used in gene therapy. They must eliminate the largest sections of the HIV genome, minimizing the chances of the virus spreading further.

With FDA clearance, the first phase of clinical trials began later this year. Scientists tested the safety of the new drug by administering it in small doses. The researchers also monitored how effectively the drug was able to eliminate the virus in patients. Subsequently, scientists hope that their development will allow to cancel antiretroviral therapy and prevent the return of the infection. Potentially, this drug will allow people with HIV to refuse lifelong treatment.

The application of CRISPR technology in humans has resulted in the widespread distribution of editing molecules and the precise cleavage and removal of integrated proviral DNA fragments from the genome of infected blood cellulars and viral reservoir tissues, including lymph nodes, spleen and cerebrum. Researchers completely freed from genetic material of human immunodeficiency virus of first type (HIV-1) patients with infected T-lymphocytes. This was done using the CRISPR system and antiretroviral therapy, while separately from each other, the methods did not give the same effect. Similar results were obtained in studies on primates. Therefore, treatment with HAART in combination with CRISPR leads to a decrease in the percentage of proviral DNA in the blood and tissues.

These observations serve as a basis for further exploration and upgrading of genome correction mechanism and represent a promising step towards eradicating HIV from human cells.

Related insights

December 1, 2022
Categories: Science

Researchers created a new surgical training model for cancer surgery

Konnyaku, a prepared jelly formed from the konjac plant’s bulb, has been efficiently used by scientists from Nagοya University to...
November 22, 2022
Categories: Science

Robotic drug capsule can carry medications to the gut

Someday, an MIT-created robotic capsule filled with medications might be able to take the place of medical injections. When this...
November 14, 2022
Categories: Science

Researchers develop a novel technique to monitor the effectiveness of treatment for cancer lesions more precisely

To better inform the development of new cancer treatments, researchers from the University of Colorado Cancer Center on the Anschutz...
November 14, 2022
Categories: Science

A specific enzyme has been discovered to play a crucial and dual role in cell health

In UMass Amherst, researchers claim to have made a significant advancement in our understanding of how cells respond to a...
November 10, 2022

Join our DAO and change the odds

ELC is an innovative cooperative tool for the decentralized development of life extension technologies. Our main mission is to accelerate...
Prev
Next

Have any questions?

Send us a request and we will contact you as soon as possible.

loader

We are in social networks

  • The goal that we have set for ourselves is the acquisition by the human body of the ability to remain young and healthy as long as possible – practically, the acquisition of immortality by a person.

    A young man at 100 years of age? Why not? And this is just the tip of the iceberg of our plans.

  • The main and most global goal of the project is to gain immortality. However, to achieve this goal, there is a lot of work to be done: from introducing the latest developments in medical practice, which already now can significantly improve health and prolong life, to conducting scientific research that will help achieve our global goal.

  • A fund or a company interested in investing in our project can contact us via the contact form to clarify all the details. The main condition is the sharing of project values ​​and the desire to change the world for the better together with us.

    In addition, we plan to issue our own token, by purchasing which you will also be able to invest in the project.

  • Since we create the ELC project from scratch and fully cover all our activities in social networks, you can learn about all promotions and developments from our official pages and website. One of the first public results will be the presentation of the project at the Eternity Life Forum, where we will present our project, with its ideas and developments.